The Valley Desk

NCT04542070 · Interventional trial

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

Overall registry status Completed

Phase 3

Conditions HIV Infections

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov